NL7018334A - - Google Patents

Info

Publication number
NL7018334A
NL7018334A NL7018334A NL7018334A NL7018334A NL 7018334 A NL7018334 A NL 7018334A NL 7018334 A NL7018334 A NL 7018334A NL 7018334 A NL7018334 A NL 7018334A NL 7018334 A NL7018334 A NL 7018334A
Authority
NL
Netherlands
Application number
NL7018334A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7018334A publication Critical patent/NL7018334A/xx

Links

NL7018334A 1969-12-19 1970-12-16 NL7018334A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88679969A 1969-12-19 1969-12-19

Publications (1)

Publication Number Publication Date
NL7018334A true NL7018334A (fr) 1971-06-22

Family

ID=25389797

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7018334A NL7018334A (fr) 1969-12-19 1970-12-16

Country Status (9)

Country Link
JP (1) JPS4948542B1 (fr)
BE (1) BE760492A (fr)
CH (1) CH535201A (fr)
DE (1) DE2062620A1 (fr)
ES (1) ES386601A1 (fr)
FR (1) FR2081388B1 (fr)
GB (1) GB1330878A (fr)
NL (1) NL7018334A (fr)
ZA (1) ZA708468B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5875614A (ja) * 1981-10-28 1983-05-07 Matsushita Electric Ind Co Ltd 焼却炉の排ガス浄化装置
DE4312016A1 (de) * 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
DE19619665C2 (de) * 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
BRPI0002693B8 (pt) * 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
KR101271263B1 (ko) 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
WO2013087090A1 (fr) 2011-12-12 2013-06-20 Auris Medical Ag Traitement de l'acouphène par modulation du co-transporteur chlorure nkcc1 dans le système auditif
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CN110218157B (zh) * 2018-03-01 2022-08-23 江苏恒瑞医药股份有限公司 一种r-氯胺酮及其可药用盐的制备方法
WO2019213551A1 (fr) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Méthodes de traitement de la toxicomanie
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
WO2020070547A1 (fr) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Régime posologique d'eskétamine pour le traitement d'un trouble dépressif majeur
EP3863617A1 (fr) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Eskétamine pour une utilisation dans le traitement d'un trouble dépressif majeur
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ,インコーポレーテッド うつ病の治療のためのエスケタミン
WO2021137148A1 (fr) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Régime posologique à base d'eskétamine pour le traitement de troubles neuropsychiatriques ou neurologiques
EP4084786A1 (fr) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Régime posologique à base d'eskétamine pour le traitement d'un trouble dépressif majeur
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
JP2023511370A (ja) 2020-01-22 2023-03-17 シーロス セラピューティクス, インコーポレイテッド Nmda拮抗薬の副作用の低減
CN112125816A (zh) * 2020-03-17 2020-12-25 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法
WO2025057111A1 (fr) 2023-09-12 2025-03-20 Clexio Biosciences Ltd. Eskétamine ou sel pharmaceutique de celle-ci destinée à être utilisée dans une méthode de traitement d'un trouble dépressif majeur

Also Published As

Publication number Publication date
FR2081388A1 (fr) 1971-12-03
JPS4948542B1 (fr) 1974-12-21
ZA708468B (en) 1972-02-23
ES386601A1 (es) 1974-01-16
GB1330878A (en) 1973-09-19
FR2081388B1 (fr) 1974-06-21
BE760492A (fr) 1971-06-17
CH535201A (de) 1973-03-31
DE2062620A1 (de) 1971-07-15

Similar Documents

Publication Publication Date Title
FR2081388B1 (fr)
AU465413B2 (fr)
AU429630B2 (fr)
CS154655B2 (fr)
AU5461069A (fr)
CS153153B1 (fr)
AU2355770A (fr)
CS152382B2 (fr)
AU5113869A (fr)
AU414607B2 (fr)
AU428074B2 (fr)
AU425297B2 (fr)
AU410358B2 (fr)
AU438128B2 (fr)
AU442285B2 (fr)
AU417208B2 (fr)
AU428129B2 (fr)
AT308690B (fr)
CS151211B1 (fr)
AR203167Q (fr)
AU4923469A (fr)
AU5079269A (fr)
AU5133369A (fr)
CS148845B1 (fr)
AU5598769A (fr)